Continuous low-dose cyclophosphamide (NSC-26271) therapy in advanced ovarian cancer

European Journal of Cancer (1965)Published 1 May 1976

Costantino Mangioni, Giorgio Bolis, Nicola Natale, L. Morasca

Citations8

TL;DR

Results demonstrate that this regimen of administration induces remission and prolongation of median survival with a very low level of toxicity and minimal discomfort to the patient.

Abstract

A low dose, continuous treatment by cyclophosphamide (100 mg/day p.o.) has been given to 141 patients with documented Müllerian ovarian cancer. From this total 134 have been evaluated for drug related toxicity. Response and survival have been studied in 72 patients in stages III, IV or in recurrence, all with at least one measurable tumor mass. Results demonstrate that this regimen of administration induces remission and prolongation of median survival with a very low level of toxicity and minimal discomfort to the patient.

Keywords

Immunology and MicrobiologyMedicine

PubMedClinical pharmacology of cyclophosphamide.

315 Citations1973Charles M. Bagley, Frieda Bostick +1 more

Although patients with and without prior exposure to microsomal enzyme-inducing drugs demonstrated marked variation in plasma cyclophosphamide half-life and peak alkylating levels, the total concentration × time product remained relatively constant for a given cycloph phosphamide dose, suggesting that alterations in the rate of cycloph phosphate metabolism by drugs or liver metastases in the absence of renal failure will not change toxicity or therapeutic effect.

New England Journal of MedicineTreatment of Ovarian Carcinoma: Possibilities for Progress

111 Citations1972Charles M. Bagley, Robert C. Young +2 more

A large number of new cases are diagnosed each year, of which 10,000 will eventually be fatal, and the number of fatal cases is expected to increase in the coming years.

American Journal of Obstetrics and GynecologyChemotherapy in the treatment of cancer of the ovary

105 Citations1970Julian P. Smith, Felix N. Rutledge

Most of the ovarian cancer patients referred to The University of Texas M. D. Anderson Hospital and Tumor Institute at Houston are not suitable for either curative operation or irradiation because their cancers are too advanced; however, about one-half profit from chemotherapy with l -phenylalanine mustard and about one -PAM, will have regression of their cancers with more intensive chemotherapy of actinomycin-D, 5-fluorouracil, and cyclophosphamide.

PubMedPhenobarbital effects on cyclophosphamide pharmacokinetics in man.

76 Citations1972John Y. Jao, William J. Jusko +1 more

Cancer Treatment ReviewsThe chemotherapy of ovarian carcinoma

56 Citations1974Robert C. Young, Susan P. Hubbard +1 more

A series of studies is proposed which may serve to optimize existing therapy in ovarian carcinoma and provide the basic information required to initiate combined modality studies in a systematic way, comparing newer modalities to optimal existing therapy within each stage.

PubMedTreatment of 126 cases of advanced ovarian carcinoma with cyclophosphamide.

48 Citations1968Rod Beck, D. A. Boyes

Cyclophosphamide was given orally to those patients who were well enough to be discharged to their homes, while those who were having more severe symptoms or were threatened with bowel obstruction received intravenous therapy.

View PDF